Bristol-Myers Squibb

AI Score

XX

Unlock

60.09
1.19 (2.02%)
At close: Mar 28, 2025, 3:59 PM
59.93
-0.26%
After-hours: Mar 28, 2025, 06:54 PM EDT

Company Description

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide.

It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.

The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma.

In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML.

It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

The company was formerly known as Bristol-Myers Company.

The company was founded in 1887 and is headquartered in New York, New York.

Bristol-Myers Squibb
Bristol-Myers Squibb logo
Country United States
IPO Date Jun 1, 1972
Industry Drug Manufacturers - General
Sector Healthcare
Employees 34,100
CEO Dr. Christopher S. Boerner Ph.D.

Contact Details

Address:
430 East 29th Street
New York, New York
United States
Website https://www.bms.com

Stock Details

Ticker Symbol BMY
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000014272
CUSIP Number 110122108
ISIN Number US1101221083
Employer ID 22-0790350
SIC Code 2834

Key Executives

Name Position
Dr. Christopher S. Boerner Ph.D. Chief Executive Officer & Chairman
David V. Elkins Executive Vice President & Chief Financial Officer
Adam Lenkowsky Executive Vice President & Chief Commercialization Officer
Ahn Amanda Poole Executive Vice President & Chief Human Resources Officer
Dr. Joseph J. Eiden Jr. Head of Medical Affairs
Greg Meyers Executive Vice President and Chief Digital & Technology Officer
Karin Shanahan Executive Vice President of Global Product Development & Supply
Kimberly M. Jablonski Chief Compliance & Ethics Officer
Samit Hirawat M.D. Executive Vice President, Chief Medical Officer & Head of Development
Sandra Leung Esq. Executive Vice President & General Counsel

Latest SEC Filings

Date Type Title
Mar 26, 2025 ARS Filing
Mar 26, 2025 DEFA14A Filing
Mar 26, 2025 DEF 14A Filing
Mar 13, 2025 SC TO-C Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing
Mar 12, 2025 4 Filing